Dimension Capital announced an $800 million third fund on July 21, 2026. The firm invests in companies that combine scientific research with artificial intelligence and powerful computing.

The New York-based firm was founded in late 2022 by Zavian Dar, Adam Goulburn, and Nan Li. Before starting Dimension, Dar and Goulburn were partners at another investment firm called Lux Capital, while Li was at Obvious Ventures.

The third fund is 60 percent larger than the firm's $500 million second fund, announced in December 2024. That second fund had itself exceeded a $400 million target. Fund III arrives about 18 months after Fund II.

Earlier reporting tracked the fund's formation. STAT News reported on March 17, 2026, that Dimension was looking to raise $700 million. Endpoints News later reported on June 4, 2026, that the firm was seeking up to $750 million. The final $800 million figure surpassed both of those reported targets.

Dimension's existing investments show where the money is going. In 2024, Dimension co-led a $30 million early investment in Chai Discovery, a company that builds AI models to help discover new drugs. By July 2026, Chai Discovery had raised $400 million and was valued at $3.8 billion.

Dimension also backed New Limit, co-founded by Coinbase CEO Brian Armstrong, at its first major funding round in January 2025. New Limit completed a later funding round at a $3.1 billion valuation as of July 2026.

On the computing side, Dimension invested in Modal Labs. The firm also became a shareholder in Anthropic, a leading AI company, when Anthropic acquired a Dimension-backed company called Coefficient Bio in spring 2026 for about $400 million. Coefficient Bio was a drug discovery platform. Dimension received Anthropic shares through that deal.

The Coefficient Bio acquisition shows an emerging pattern: leading AI companies are buying biology-focused companies not just for their staff, but for their scientific platforms and data, which can be folded into the AI company's own work. The gap between a $30 million early investment in Chai Discovery in 2024 and a $3.8 billion valuation in mid-2026 shows how quickly investors are valuing AI-powered drug discovery companies. Anthropic's roughly $400 million purchase of Coefficient Bio signals that AI labs are willing to pay for ready-made biological data and tools rather than building them from scratch.

For the institutions that invest in venture funds, Dimension's growth from a $500 million fund to an $800 million fund in 18 months reflects a broader shift of money toward firms with deep expertise where life sciences and computing meet. The increase in both fund size and speed is notable because venture fundraising has generally contracted since 2022.

In my view, what sets Dimension apart is that it invests on two fronts at once: in the scientific applications, through companies like Chai Discovery and New Limit, and in the computing infrastructure underneath, through investments like Modal Labs and the Anthropic shares it received. That means the firm benefits whether the value ends up in the AI platforms themselves or in the scientific tools built on top of them. We have seen this pattern before, during the cloud computing boom of the 2010s, when firms that invested in both the infrastructure providers and the software companies using that infrastructure earned returns from both layers of the same technology stack. Dimension appears to be applying a version of that strategy to AI infrastructure and computational science.

The third fund gives the firm the capital to keep going. What remains is execution: whether Dimension can keep finding companies at the intersection of science and computing, and whether the high valuations placed on Chai Discovery and New Limit hold up as those companies grow. For now, the money is in place.